China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its anti-depression drug, LS21031. This PDE4 inhibitor is being developed to improve symptoms of depression and cognitive-related diseases.
Mechanism of Action
LS21031 works by effectively inhibiting the activity of the PDE4 enzyme through allosteric regulation of the blood-brain barrier. This mechanism reduces the hydrolysis of cAMP, increases PKA/CREB signal transduction, and ultimately leads to the improvement of depression symptoms and cognitive function.
Company Overview and Pipeline
LanssonPharm is known for its potential best-in-class drugs targeting various CNS conditions, including ischemic stroke, brain glioma, post-traumatic stress disorder, and severe depression. The company previously advanced its Parkinson’s disease therapy, LS001, into clinical trials, demonstrating its commitment to developing innovative treatments for neurological disorders.
Significance of the Approval
The approval of LS21031 for clinical trials marks a significant milestone for LanssonPharm. It underscores the company’s ongoing efforts to address unmet medical needs in the treatment of depression and cognitive disorders, potentially offering new hope for patients in these areas.-Fineline Info & Tech
